Nuveen’s Galectin Therapeutics GALT Stock Holding History

Nuveen’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-27,623	Closed	-$33.7K	–	3311
2025 Q1	$33.7K	Hold	27,623	–	–	﹤0.01%	3272
2024 Q4	$35.6K	Hold	27,623	–	–	﹤0.01%	3320
2024 Q3	$76K	Hold	27,623	–	–	﹤0.01%	3320
2024 Q2	$62.4K	Buy	+27,623	New	+$83.9K	﹤0.01%	3321
2021 Q2	–	Sell	-177,035	Closed	-$384K	–	3436
2021 Q1	$384K	Sell	177,035 -7,816	-4%	-$17.5K	﹤0.01%	3133
2020 Q4	$414K	Buy	184,851 +2,965	+2%	+$7.78K	﹤0.01%	3081
2020 Q3	$486K	Sell	181,886 -57	-0%	-$160	﹤0.01%	2965
2020 Q2	$556K	Buy	181,943 +51,921	+40%	+$131K	﹤0.01%	2856
2020 Q1	$255K	Buy	130,022 +22,750	+21%	+$55.4K	﹤0.01%	2954
2019 Q4	$307K	Sell	107,272 -14,942	-12%	-$51.9K	﹤0.01%	3003
2019 Q3	$449K	Buy	122,214 +41,251	+51%	+$149K	﹤0.01%	2977
2019 Q2	$336K	Buy	+80,963	New	+$351K	﹤0.01%	3099

Other funds holding GALT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return

GWM

Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Nuveen's GALT Position: Q2 2025 in Review

Nuveen sold out of Galectin Therapeutics (GALT) in Q2 2025, closing a stake of 27,623 shares — an estimated $33.7K sold.

Nuveen first reported a position in GALT in Q2 2019 and held it in 12 quarters. The position peaked at $556K in Q2 2020. 86 funds tracked by Wall St. Rank hold GALT as of Q2 2025.

Nuveen reported no remaining Galectin Therapeutics position as of Q2 2025 after selling out during the quarter.
Nuveen sold 27,623 Galectin Therapeutics shares in Q2 2025, an estimated $33.7K.
Nuveen first reported a position in Galectin Therapeutics in Q2 2019 and held it in 12 quarters.
Nuveen's Galectin Therapeutics position peaked at $556K in Q2 2020.
86 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2025.

Based on Nuveen's 13F filing for Q2 2025, filed 12 Aug 2025.